BioDome Partners announces exclusive option deal with Children's Hospital Los Angeles


BioDome Partners, LLC and Children’s Hospital Los Angeles (CHLA) announced today that they have entered into an option agreement under which BioDome Partners has the exclusive right to secure an exclusive license for technology and IP of CHLA pertaining to the use of neuregulin-4 (NRG-4) for the treatment of inflammatory bowel disease (IBD) and necrotizing enterocolitis (NEC). 

“This option agreement with CHLA is an example of our focus and dedication to identify and mobilize potential game changing therapies to serve patients in need,” said Artin Asadourian, Managing Partner of BioDome Partners.  “We are pleased to continue to collaborate with CHLA on the development of NRG-4 through this mutually beneficial agreement which provides BioDome Partners the exclusive rights to license NRG-4 in the near future.”

Added Dr. David Maggs, Managing Partner, BioDome Partners, “The pre-clinical NRG-4 results in both IBD and NEC models are impressive, and demonstrate a real potential to change the way these diseases may be treated in the future.” 

“We are delighted to be working with BioDome Partners on this opportunity to open a new potential therapeutic avenue for necrotizing enterocolitis and other intestinal disorders”, said Mark Frey, PhD, Assistant Professor of Pediatrics and Biochemistry and Molecular Biology at the Saban Research Institute at Children's Hospital Los Angeles. “NRG4-induced epithelial cell survival represents a powerful endogenous mechanism for restraining inflammation-induced intestinal damage, which we hypothesize can be harnessed therapeutically.”

“As CHLA continues to grow its translational assets and capabilities, this collaboration with the BioDome team solidifies our goal of effectively translating our research to the clinic with an ideal set of partners, and we look forward to a fruitful collaboration” added Jessica Rousset, director, CHLA Center for Innovation.


For the full press release please see the following link:

http://www.prweb.com/releases/2014/06/prweb11961320.htm​